This is particularly marked in breast carcinoma cancer cell lines, with MCL1‐ and MARCH5‐dependent cells having similar sensitivity to haematologic cancer cell lines (acute myeloid leukaemia), where MCL1 inhibitors are in clinical development (Fig 4C). The gene discussed is MCL1; the disease is acute myeloid leukemia.